<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059435</url>
  </required_header>
  <id_info>
    <org_study_id>20060220</org_study_id>
    <nct_id>NCT01059435</nct_id>
  </id_info>
  <brief_title>A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Ascending Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability of romosozumab
      following single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and
      postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2006</start_date>
  <completion_date type="Actual">July 6, 2007</completion_date>
  <primary_completion_date type="Actual">July 6, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Adverse events were collected from the first dose of treatment up until day 29 for the 0.1 mg/kg and 0.3 mg/kg SC treatment groups, up to 57 days for the 1 mg/kg and 3 mg/kg IV/SC groups and for up to 85 days for the 5 mg/kg and 10 mg/kg SC/IV groups.</time_frame>
    <description>Serious adverse events were any events that were fatal, were life-threatening (placed the participant at immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, were congenital anomalies or birth defects, or were other significant medical hazards.
Relatedness to investigational product was assessed by the investigator by means of the question: &quot;Is there a reasonable possibility that the event may have been caused by the investigational product?'</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Developed Anti-romosozumab Antibodies</measure>
    <time_frame>Day 29 (all participants), day 57 (1, 3, 5, and 10 mg/kg treatment groups only) and at day 85 (5 and 10 mg/kg teatment groups only).</time_frame>
    <description>Binding anti-romosozumab antibody titers were assessed using a validated electrochemiluninescence (ECL) immunoassay. The limit of detection for this assay was 3.91 ng/mL of anti-romosozumab antibody in neat serum. Samples found to be positive for binding antibodies were further tested using a validated bioassay to determine if the antibodies were able to neutralize the activity of romosozumab. The limit of detection for this assay was ≥ 0.75 μg/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Romosozumab</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) of Romosozumab</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial Concentration Following IV Administration (C0) of Romosozumab</measure>
    <time_frame>Day 1 at the end of infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-time Curve From Time Zero to Infinity for Romosozumab</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) / Clearance (CL) for Romosozumab</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life Associated With the Beta (Plateau) Phase of Elimination for Romosozumab</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>The plateau (beta, β) phase half-life (t½,β) was calculated from the natural log of 2 divided by the beta phase rate constant (λβ). λβ for a subject was estimated by linear regression of at least 3 contiguous time points that followed the Cmax and constituted a distinct phase that preceded the terminal phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life Associated With the Gamma (Terminal) Phase of Elimination for Romosozumab</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>The terminal (gamma, γ) phase half-life (t½,γ) was calculated from the natural log of 2 divided by the terminal rate constant (λz).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Effect for Serum Type 1 Aminoterminal Propeptide (P1NP)</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>Defined as the maximum value postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Effect of P1NP</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>Defined as the time to maximum value postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for P1NP</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for P1NP</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab,</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Effect for Serum C-telopeptide (sCTX)</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>Defined as the minimum value postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Effect of sCTX</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>Defined as the time to minimum value postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for sCTX</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for sCTX</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Effect for Osteocalcin</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>Defined as the maximum value postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Effect of Osteocalcin</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>Defined as the time to maximum value postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for Osteocalcin</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for Osteocalcin</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Effect for Bone-specific Alkaline Phosphatase (BSAP)</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>Defined as the maximum value postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Effect of BSAP</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>Defined as the time to maximum value postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for BSAP</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for BSAP</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Effect for Intact Parathyroid Hormone (iPTH)</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>Defined as the maximum value postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Effect of iPTH</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
    <description>Defined as the time to maximum value postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for iPTH</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Day 0 to the Last Sampling Timepoint (AUC0-t) for iPTH</measure>
    <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Sclerostin</measure>
    <time_frame>Baseline and days 15, 29, 43, 57, 71, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium Over Time</measure>
    <time_frame>Dday 1 predose and at 4, 6, 8, 10, and 12 hours, days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ionized Calcium Over Time</measure>
    <time_frame>Day 1 predose and at 4, 6, 8, 10, 12 hours, days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants were randomized to receive a single dose of matching placebo administered by subcutaneous or intravenous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were randomized to receive a single dose of romosozumab administered by subcutaneous or intravenous injection. The starting dose was 0.1 mg/kg, with sequential escalation up to 10 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Administered subcutaneously or intravenously</description>
    <arm_group_label>Romosozumab</arm_group_label>
    <other_name>AMG 785</other_name>
    <other_name>EVENITY™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered subcutaneously or intravenously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or female between 45 to 59 years of age, inclusive

          -  Postmenopausal females defined as 12 continuous months of spontaneous amenorrhea
             confirmed by a serum follicle-stimulating hormone (FSH) result &gt; 40mIU/mL, or 6 weeks
             postsurgical bilateral oophorectomy (with or without hysterectomy)

          -  Males must agree to use a condom during sexual intercourse with female partners who
             are of reproductive potential and to have their female partners use an additional
             effective means of contraception or to abstain from sexual intercourse for the
             duration of the study

          -  Has no history or evidence of a clinically significant disorder, condition or disease
             that would pose a risk to subject safety or interfere with the study evaluation,
             procedures or completion

        Exclusion Criteria:

          -  Diagnosed with any condition that will affect bone metabolism

          -  Administration of the following medications within 6 months before study drug
             administration:

          -  Hormone replacement therapy [Infrequent use of estrogen vaginal creams (&lt; 3 times per
             week) is allowed.]

          -  Calcitonin

          -  Parathyroid hormone (or any derivative)

          -  Supplemental Vitamin D &gt; 1,000 IU/day

          -  Glucocorticosteroids (inhaled or topical corticosteroids administered more than 2
             weeks before the enrollment date are allowed)

          -  Anabolic steroids

          -  Calcitriol, and available analogues

          -  Administration of the following medications within 12 months before study drug
             administration:

          -  Bisphosphonates

          -  Fluoride for osteoporosis

          -  Administration of herbal medications within 2 weeks or 5 half-lives (whichever is
             longer) before study drug administration

          -  Greatly differing levels of physical activity or constant levels of intense physical
             exercise during the 6 months before study drug administration

          -  Routine alcohol intake of &gt; 2 drinks per day, on average, within 6 months of study
             drug administration

          -  Known sensitivity to mammalian-derived drug preparations

          -  Known to be hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency
             virus (HIV) positive, or a known diagnosis of acquired immunodeficiency syndrome
             (AIDS)

          -  Any organic or psychiatric disorder which may pose a risk to subject safety and may
             prevent the subject from completing the study or interfere with the interpretation of
             the study results

          -  Unavailable for follow-up assessment or any concerns for subject's compliance with the
             protocol procedures

          -  Any other condition that might reduce the chance of obtaining data required by the
             protocol or that might compromise the ability to give truly informed consent

          -  Has a history of drug or alcohol abuse with the last 12 months and/or a positive urine
             test result at screening or admission

          -  Has any clinically significant abnormality during the screening physical examination,
             electrocardiogram (ECG), or laboratory evaluation

          -  Has participated in another clinical study within 4 weeks of screening or within 5
             times the half-life of the investigational agent in the other clinical study, if known

          -  Weight ≥ 98 kilograms (216 pounds) and/or height ≥ 78 inches

          -  Has donated or lost 400 milliliters or more of blood or plasma within 8 weeks of study
             drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011 Jan;26(1):19-26. doi: 10.1002/jbmr.173.</citation>
    <PMID>20593411</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <results_first_submitted>April 10, 2019</results_first_submitted>
  <results_first_submitted_qc>July 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>July 3, 2019</last_update_submitted>
  <last_update_submitted_qc>July 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amgen</keyword>
  <keyword>First in Human</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a single-center study conducted in the USA. The first participant enrolled on 13 December 2006 and the last participant completed the study on 06 July 2007.</recruitment_details>
      <pre_assignment_details>Participants were enrolled sequentially into 1 of 6 dose cohorts. Healthy postmenopausal women were randomized to romosozumab or placebo in a 3:1 ratio at 0.1, 0.3, 1 mg/kg SC, 1 mg/kg IV, 3, 5 mg/kg SC, 10 mg/kg SC, or 10 mg/kg IV; healthy men received romosozumab SC or IV, placebo SC or IV in a 3:3:1:1 ratio at doses of 1 mg/kg or 10 mg/kg.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo SC</title>
          <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
        </group>
        <group group_id="P2">
          <title>Romosozumab 0.1 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
        </group>
        <group group_id="P3">
          <title>Romosozumab 0.3 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
        </group>
        <group group_id="P4">
          <title>Romosozumab 1.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="P5">
          <title>Romosozumab 3.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="P6">
          <title>Romosozumab 5.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="P7">
          <title>Romosozumab 10.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="P8">
          <title>Placebo IV</title>
          <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
        </group>
        <group group_id="P9">
          <title>Romosozumab 1.0 mg/kg IV</title>
          <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="P10">
          <title>Romosozumab 5.0 mg/kg IV</title>
          <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated participants</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo SC</title>
          <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
        </group>
        <group group_id="B2">
          <title>Romosozumab 0.1 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
        </group>
        <group group_id="B3">
          <title>Romosozumab 0.3 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
        </group>
        <group group_id="B4">
          <title>Romosozumab 1.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="B5">
          <title>Romosozumab 3.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="B6">
          <title>Romosozumab 5.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="B7">
          <title>Romosozumab 10.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="B8">
          <title>Placebo IV</title>
          <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
        </group>
        <group group_id="B9">
          <title>Romosozumab 1.0 mg/kg IV</title>
          <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="B10">
          <title>Romosozumab 5.0 mg/kg IV</title>
          <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>SC Dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.79" spread="4.17"/>
                    <measurement group_id="B2" value="53.00" spread="3.95"/>
                    <measurement group_id="B3" value="53.33" spread="3.20"/>
                    <measurement group_id="B4" value="52.00" spread="4.64"/>
                    <measurement group_id="B5" value="55.00" spread="4.05"/>
                    <measurement group_id="B6" value="51.89" spread="2.32"/>
                    <measurement group_id="B7" value="52.50" spread="4.32"/>
                    <measurement group_id="B8" value="NA" spread="NA">SC dosing cohorts are reported in this row</measurement>
                    <measurement group_id="B9" value="NA" spread="NA">SC dosing cohorts are reported in this row</measurement>
                    <measurement group_id="B10" value="NA" spread="NA">SC dosing cohorts are reported in this row</measurement>
                    <measurement group_id="B11" value="52.80" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV Dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" spread="NA">IV dosing cohorts are reported in this row</measurement>
                    <measurement group_id="B2" value="NA" spread="NA">IV dosing cohorts are reported in this row</measurement>
                    <measurement group_id="B3" value="NA" spread="NA">IV dosing cohorts are reported in this row</measurement>
                    <measurement group_id="B4" value="NA" spread="NA">IV dosing cohorts are reported in this row</measurement>
                    <measurement group_id="B5" value="NA" spread="NA">IV dosing cohorts are reported in this row</measurement>
                    <measurement group_id="B6" value="NA" spread="NA">IV dosing cohorts are reported in this row</measurement>
                    <measurement group_id="B7" value="NA" spread="NA">IV dosing cohorts are reported in this row</measurement>
                    <measurement group_id="B8" value="52.50" spread="4.43"/>
                    <measurement group_id="B9" value="49.33" spread="4.63"/>
                    <measurement group_id="B10" value="51.00" spread="3.35"/>
                    <measurement group_id="B11" value="50.75" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White or Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Serious adverse events were any events that were fatal, were life-threatening (placed the participant at immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, were congenital anomalies or birth defects, or were other significant medical hazards.
Relatedness to investigational product was assessed by the investigator by means of the question: &quot;Is there a reasonable possibility that the event may have been caused by the investigational product?'</description>
        <time_frame>Adverse events were collected from the first dose of treatment up until day 29 for the 0.1 mg/kg and 0.3 mg/kg SC treatment groups, up to 57 days for the 1 mg/kg and 3 mg/kg IV/SC groups and for up to 85 days for the 5 mg/kg and 10 mg/kg SC/IV groups.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Serious adverse events were any events that were fatal, were life-threatening (placed the participant at immediate risk of death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, were congenital anomalies or birth defects, or were other significant medical hazards.
Relatedness to investigational product was assessed by the investigator by means of the question: &quot;Is there a reasonable possibility that the event may have been caused by the investigational product?'</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious treatment-related adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Developed Anti-romosozumab Antibodies</title>
        <description>Binding anti-romosozumab antibody titers were assessed using a validated electrochemiluninescence (ECL) immunoassay. The limit of detection for this assay was 3.91 ng/mL of anti-romosozumab antibody in neat serum. Samples found to be positive for binding antibodies were further tested using a validated bioassay to determine if the antibodies were able to neutralize the activity of romosozumab. The limit of detection for this assay was ≥ 0.75 μg/mL.</description>
        <time_frame>Day 29 (all participants), day 57 (1, 3, 5, and 10 mg/kg treatment groups only) and at day 85 (5 and 10 mg/kg teatment groups only).</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Anti-romosozumab Antibodies</title>
          <description>Binding anti-romosozumab antibody titers were assessed using a validated electrochemiluninescence (ECL) immunoassay. The limit of detection for this assay was 3.91 ng/mL of anti-romosozumab antibody in neat serum. Samples found to be positive for binding antibodies were further tested using a validated bioassay to determine if the antibodies were able to neutralize the activity of romosozumab. The limit of detection for this assay was ≥ 0.75 μg/mL.</description>
          <population>All treated participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Binding antibody positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing antibody positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of Romosozumab</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants who received subcutaneous romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Romosozumab</title>
          <population>All treated participants who received subcutaneous romosozumab</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375" spread="182"/>
                    <measurement group_id="O2" value="1280" spread="653"/>
                    <measurement group_id="O3" value="4890" spread="1780"/>
                    <measurement group_id="O4" value="21300" spread="5170"/>
                    <measurement group_id="O5" value="33500" spread="8290"/>
                    <measurement group_id="O6" value="75200" spread="15900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Concentration (Tmax) of Romosozumab</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants who received subcutaneous romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) of Romosozumab</title>
          <population>All treated participants who received subcutaneous romosozumab</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.5" upper_limit="7"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O3" value="3" lower_limit="2" upper_limit="14"/>
                    <measurement group_id="O4" value="5" lower_limit="4" upper_limit="7"/>
                    <measurement group_id="O5" value="5" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="O6" value="4.5" lower_limit="2" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Initial Concentration Following IV Administration (C0) of Romosozumab</title>
        <time_frame>Day 1 at the end of infusion</time_frame>
        <population>All treated participants who received intravenously administered romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Concentration Following IV Administration (C0) of Romosozumab</title>
          <population>All treated participants who received intravenously administered romosozumab</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24900" spread="4670"/>
                    <measurement group_id="O2" value="132000" spread="13700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Serum Concentration-time Curve From Time Zero to Infinity for Romosozumab</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants who received romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Serum Concentration-time Curve From Time Zero to Infinity for Romosozumab</title>
          <population>All treated participants who received romosozumab</population>
          <units>µg*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" spread="22.6"/>
                    <measurement group_id="O2" value="288" spread="144"/>
                    <measurement group_id="O3" value="1480" spread="605"/>
                    <measurement group_id="O4" value="8170" spread="1810"/>
                    <measurement group_id="O5" value="16900" spread="4350"/>
                    <measurement group_id="O6" value="43400" spread="8550"/>
                    <measurement group_id="O7" value="3020" spread="989"/>
                    <measurement group_id="O8" value="24400" spread="4400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F) / Clearance (CL) for Romosozumab</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants who received romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) / Clearance (CL) for Romosozumab</title>
          <population>All treated participants who received romosozumab</population>
          <units>mL/hr/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.489"/>
                    <measurement group_id="O2" value="1.35" spread="0.841"/>
                    <measurement group_id="O3" value="0.873" spread="0.647"/>
                    <measurement group_id="O4" value="0.383" spread="0.0901"/>
                    <measurement group_id="O5" value="0.319" spread="0.0998"/>
                    <measurement group_id="O6" value="0.236" spread="0.0370"/>
                    <measurement group_id="O7" value="0.362" spread="0.117"/>
                    <measurement group_id="O8" value="0.210" spread="0.0361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life Associated With the Beta (Plateau) Phase of Elimination for Romosozumab</title>
        <description>The plateau (beta, β) phase half-life (t½,β) was calculated from the natural log of 2 divided by the beta phase rate constant (λβ). λβ for a subject was estimated by linear regression of at least 3 contiguous time points that followed the Cmax and constituted a distinct phase that preceded the terminal phase.</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants who received 3, 5, or 10 mg/kg romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life Associated With the Beta (Plateau) Phase of Elimination for Romosozumab</title>
          <description>The plateau (beta, β) phase half-life (t½,β) was calculated from the natural log of 2 divided by the beta phase rate constant (λβ). λβ for a subject was estimated by linear regression of at least 3 contiguous time points that followed the Cmax and constituted a distinct phase that preceded the terminal phase.</description>
          <population>All treated participants who received 3, 5, or 10 mg/kg romosozumab</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="11.1" spread="3.70"/>
                    <measurement group_id="O5" value="12.9" spread="3.14"/>
                    <measurement group_id="O6" value="18.0" spread="3.54"/>
                    <measurement group_id="O8" value="10.6" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life Associated With the Gamma (Terminal) Phase of Elimination for Romosozumab</title>
        <description>The terminal (gamma, γ) phase half-life (t½,γ) was calculated from the natural log of 2 divided by the terminal rate constant (λz).</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants who received romosozumab</population>
        <group_list>
          <group group_id="O1">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life Associated With the Gamma (Terminal) Phase of Elimination for Romosozumab</title>
          <description>The terminal (gamma, γ) phase half-life (t½,γ) was calculated from the natural log of 2 divided by the terminal rate constant (λz).</description>
          <population>All treated participants who received romosozumab</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.20" spread="1.36"/>
                    <measurement group_id="O2" value="5.13" spread="0.640"/>
                    <measurement group_id="O3" value="5.50" spread="0.322"/>
                    <measurement group_id="O4" value="6.68" spread="0.961"/>
                    <measurement group_id="O5" value="5.81" spread="0.874"/>
                    <measurement group_id="O6" value="5.88" spread="1.60"/>
                    <measurement group_id="O7" value="4.49" spread="0.974"/>
                    <measurement group_id="O8" value="4.93" spread="0.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Effect for Serum Type 1 Aminoterminal Propeptide (P1NP)</title>
        <description>Defined as the maximum value postdose.</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect for Serum Type 1 Aminoterminal Propeptide (P1NP)</title>
          <description>Defined as the maximum value postdose.</description>
          <population>All treated participants</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" spread="32.0"/>
                    <measurement group_id="O2" value="57.7" spread="22.8"/>
                    <measurement group_id="O3" value="60.9" spread="14.4"/>
                    <measurement group_id="O4" value="60.7" spread="10.8"/>
                    <measurement group_id="O5" value="100.8" spread="49.6"/>
                    <measurement group_id="O6" value="125.1" spread="44.2"/>
                    <measurement group_id="O7" value="141.4" spread="24.8"/>
                    <measurement group_id="O8" value="77.0" spread="35.3"/>
                    <measurement group_id="O9" value="76.3" spread="19.8"/>
                    <measurement group_id="O10" value="173.4" spread="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Effect of P1NP</title>
        <description>Defined as the time to maximum value postdose.</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Effect of P1NP</title>
          <description>Defined as the time to maximum value postdose.</description>
          <population>All treated participants</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" lower_limit="1.0" upper_limit="64.0"/>
                    <measurement group_id="O2" value="11.0" lower_limit="6.0" upper_limit="29.0"/>
                    <measurement group_id="O3" value="4.5" lower_limit="1.0" upper_limit="15.0"/>
                    <measurement group_id="O4" value="15.0" lower_limit="11.0" upper_limit="57.0"/>
                    <measurement group_id="O5" value="22.0" lower_limit="15.0" upper_limit="22.0"/>
                    <measurement group_id="O6" value="22.0" lower_limit="15.0" upper_limit="29.0"/>
                    <measurement group_id="O7" value="25.5" lower_limit="22.0" upper_limit="36.0"/>
                    <measurement group_id="O8" value="43.0" lower_limit="1.0" upper_limit="57.0"/>
                    <measurement group_id="O9" value="15.0" lower_limit="11.0" upper_limit="22.0"/>
                    <measurement group_id="O10" value="18.5" lower_limit="15.0" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for P1NP</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for P1NP</title>
          <population>All treated participants</population>
          <units>days*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1529" spread="633"/>
                    <measurement group_id="O2" value="1431" spread="548"/>
                    <measurement group_id="O3" value="1564" spread="377"/>
                    <measurement group_id="O4" value="1473" spread="304"/>
                    <measurement group_id="O5" value="2300" spread="1099"/>
                    <measurement group_id="O6" value="2780" spread="1007"/>
                    <measurement group_id="O7" value="2986" spread="306"/>
                    <measurement group_id="O8" value="1714" spread="782"/>
                    <measurement group_id="O9" value="1794" spread="434"/>
                    <measurement group_id="O10" value="3940" spread="944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for P1NP</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab,</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for P1NP</title>
          <population>All treated participants</population>
          <units>days*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3234" spread="1462"/>
                    <measurement group_id="O2" value="1431" spread="548"/>
                    <measurement group_id="O3" value="1564" spread="377"/>
                    <measurement group_id="O4" value="2782" spread="513"/>
                    <measurement group_id="O5" value="3962" spread="1702"/>
                    <measurement group_id="O6" value="6759" spread="2434"/>
                    <measurement group_id="O7" value="7846" spread="1264"/>
                    <measurement group_id="O8" value="4487" spread="2352"/>
                    <measurement group_id="O9" value="3138" spread="723"/>
                    <measurement group_id="O10" value="8976" spread="2531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Effect for Serum C-telopeptide (sCTX)</title>
        <description>Defined as the minimum value postdose.</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect for Serum C-telopeptide (sCTX)</title>
          <description>Defined as the minimum value postdose.</description>
          <population>All treated participants</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.2"/>
                    <measurement group_id="O2" value="0.4" spread="0.2"/>
                    <measurement group_id="O3" value="0.3" spread="0.1"/>
                    <measurement group_id="O4" value="0.3" spread="0.1"/>
                    <measurement group_id="O5" value="0.4" spread="0.1"/>
                    <measurement group_id="O6" value="0.2" spread="0.1"/>
                    <measurement group_id="O7" value="0.2" spread="0.1"/>
                    <measurement group_id="O8" value="0.3" spread="0.2"/>
                    <measurement group_id="O9" value="0.2" spread="0.1"/>
                    <measurement group_id="O10" value="0.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Effect of sCTX</title>
        <description>Defined as the time to minimum value postdose.</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Effect of sCTX</title>
          <description>Defined as the time to minimum value postdose.</description>
          <population>All treated participants</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="36.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="43.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="1.0" upper_limit="50.0"/>
                    <measurement group_id="O6" value="8.0" lower_limit="1.0" upper_limit="78.0"/>
                    <measurement group_id="O7" value="6.0" lower_limit="1.0" upper_limit="22.0"/>
                    <measurement group_id="O8" value="18.5" lower_limit="1.0" upper_limit="43.0"/>
                    <measurement group_id="O9" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O10" value="1.0" lower_limit="1.0" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for sCTX</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for sCTX</title>
          <population>All treated participants</population>
          <units>days*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="8"/>
                    <measurement group_id="O2" value="21" spread="6"/>
                    <measurement group_id="O3" value="18" spread="5"/>
                    <measurement group_id="O4" value="15" spread="6"/>
                    <measurement group_id="O5" value="14" spread="3"/>
                    <measurement group_id="O6" value="11" spread="4"/>
                    <measurement group_id="O7" value="8" spread="3"/>
                    <measurement group_id="O8" value="21" spread="8"/>
                    <measurement group_id="O9" value="13" spread="3"/>
                    <measurement group_id="O10" value="12" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for sCTX</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for sCTX</title>
          <population>All treated participants</population>
          <units>days*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" spread="18"/>
                    <measurement group_id="O2" value="21" spread="6"/>
                    <measurement group_id="O3" value="18" spread="5"/>
                    <measurement group_id="O4" value="30" spread="13"/>
                    <measurement group_id="O5" value="29" spread="7"/>
                    <measurement group_id="O6" value="41" spread="18"/>
                    <measurement group_id="O7" value="40" spread="15"/>
                    <measurement group_id="O8" value="44" spread="20"/>
                    <measurement group_id="O9" value="26" spread="6"/>
                    <measurement group_id="O10" value="44" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Effect for Osteocalcin</title>
        <description>Defined as the maximum value postdose.</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect for Osteocalcin</title>
          <description>Defined as the maximum value postdose.</description>
          <population>All treated participants</population>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9" spread="8.1"/>
                    <measurement group_id="O2" value="25.6" spread="8.0"/>
                    <measurement group_id="O3" value="25.8" spread="4.8"/>
                    <measurement group_id="O4" value="26.6" spread="5.5"/>
                    <measurement group_id="O5" value="36.9" spread="10.9"/>
                    <measurement group_id="O6" value="39.0" spread="12.7"/>
                    <measurement group_id="O7" value="53.9" spread="10.5"/>
                    <measurement group_id="O8" value="35.9" spread="13.9"/>
                    <measurement group_id="O9" value="28.8" spread="7.7"/>
                    <measurement group_id="O10" value="53.5" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Effect of Osteocalcin</title>
        <description>Defined as the time to maximum value postdose.</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Effect of Osteocalcin</title>
          <description>Defined as the time to maximum value postdose.</description>
          <population>All treated participants</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0" lower_limit="2.0" upper_limit="57.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="2.0" upper_limit="15.0"/>
                    <measurement group_id="O3" value="18.5" lower_limit="2.0" upper_limit="38.0"/>
                    <measurement group_id="O4" value="22.0" lower_limit="11.0" upper_limit="36.0"/>
                    <measurement group_id="O5" value="22.0" lower_limit="22.0" upper_limit="29.0"/>
                    <measurement group_id="O6" value="29.0" lower_limit="29.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="36.0" lower_limit="26.0" upper_limit="57.0"/>
                    <measurement group_id="O8" value="34.0" lower_limit="5.0" upper_limit="64.0"/>
                    <measurement group_id="O9" value="22.0" lower_limit="11.0" upper_limit="36.0"/>
                    <measurement group_id="O10" value="32.5" lower_limit="29.0" upper_limit="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for Osteocalcin</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for Osteocalcin</title>
          <population>All treated participants</population>
          <units>days*µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="617" spread="209"/>
                    <measurement group_id="O2" value="611" spread="191"/>
                    <measurement group_id="O3" value="658" spread="153"/>
                    <measurement group_id="O4" value="570" spread="139"/>
                    <measurement group_id="O5" value="753" spread="234"/>
                    <measurement group_id="O6" value="757" spread="225"/>
                    <measurement group_id="O7" value="881" spread="162"/>
                    <measurement group_id="O8" value="759" spread="286"/>
                    <measurement group_id="O9" value="559" spread="73"/>
                    <measurement group_id="O10" value="973" spread="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for Osteocalcin</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for Osteocalcin</title>
          <population>All treated participants</population>
          <units>days*µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1259" spread="505"/>
                    <measurement group_id="O2" value="611" spread="191"/>
                    <measurement group_id="O3" value="658" spread="153"/>
                    <measurement group_id="O4" value="1129" spread="256"/>
                    <measurement group_id="O5" value="1487" spread="453"/>
                    <measurement group_id="O6" value="2470" spread="827"/>
                    <measurement group_id="O7" value="2964" spread="563"/>
                    <measurement group_id="O8" value="1897" spread="519"/>
                    <measurement group_id="O9" value="1132" spread="131"/>
                    <measurement group_id="O10" value="2988" spread="460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Effect for Bone-specific Alkaline Phosphatase (BSAP)</title>
        <description>Defined as the maximum value postdose.</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect for Bone-specific Alkaline Phosphatase (BSAP)</title>
          <description>Defined as the maximum value postdose.</description>
          <population>All treated participants</population>
          <units>µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" spread="5.7"/>
                    <measurement group_id="O2" value="18.0" spread="6.7"/>
                    <measurement group_id="O3" value="17.2" spread="3.2"/>
                    <measurement group_id="O4" value="17.7" spread="4.7"/>
                    <measurement group_id="O5" value="26.1" spread="7.8"/>
                    <measurement group_id="O6" value="24.6" spread="8.6"/>
                    <measurement group_id="O7" value="29.9" spread="8.2"/>
                    <measurement group_id="O8" value="19.6" spread="3.7"/>
                    <measurement group_id="O9" value="15.9" spread="4.5"/>
                    <measurement group_id="O10" value="36.4" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Effect of BSAP</title>
        <description>Defined as the time to maximum value postdose.</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Effect of BSAP</title>
          <description>Defined as the time to maximum value postdose.</description>
          <population>All treated participants</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" lower_limit="4.0" upper_limit="78.0"/>
                    <measurement group_id="O2" value="16.5" lower_limit="4.0" upper_limit="29.0"/>
                    <measurement group_id="O3" value="13.0" lower_limit="6.0" upper_limit="19.0"/>
                    <measurement group_id="O4" value="15.0" lower_limit="8.0" upper_limit="29.0"/>
                    <measurement group_id="O5" value="22.0" lower_limit="22.0" upper_limit="22.0"/>
                    <measurement group_id="O6" value="22.0" lower_limit="22.0" upper_limit="36.0"/>
                    <measurement group_id="O7" value="22.0" lower_limit="15.0" upper_limit="29.0"/>
                    <measurement group_id="O8" value="46.5" lower_limit="6.0" upper_limit="85.0"/>
                    <measurement group_id="O9" value="13.5" lower_limit="6.0" upper_limit="50.0"/>
                    <measurement group_id="O10" value="29.0" lower_limit="22.0" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for BSAP</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for BSAP</title>
          <population>All treated participants</population>
          <units>days*µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462" spread="157"/>
                    <measurement group_id="O2" value="460" spread="172"/>
                    <measurement group_id="O3" value="460" spread="127"/>
                    <measurement group_id="O4" value="422" spread="100"/>
                    <measurement group_id="O5" value="588" spread="152"/>
                    <measurement group_id="O6" value="540" spread="210"/>
                    <measurement group_id="O7" value="639" spread="176"/>
                    <measurement group_id="O8" value="448" spread="73"/>
                    <measurement group_id="O9" value="376" spread="102"/>
                    <measurement group_id="O10" value="780" spread="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for BSAP</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Day 0 to the Last Sampling Time Point (AUC0-t) for BSAP</title>
          <population>All treated participants</population>
          <units>days*µg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="958" spread="428"/>
                    <measurement group_id="O2" value="460" spread="172"/>
                    <measurement group_id="O3" value="460" spread="127"/>
                    <measurement group_id="O4" value="815" spread="190"/>
                    <measurement group_id="O5" value="1120" spread="303"/>
                    <measurement group_id="O6" value="1496" spread="527"/>
                    <measurement group_id="O7" value="1860" spread="508"/>
                    <measurement group_id="O8" value="1138" spread="191"/>
                    <measurement group_id="O9" value="731" spread="177"/>
                    <measurement group_id="O10" value="2033" spread="780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Effect for Intact Parathyroid Hormone (iPTH)</title>
        <description>Defined as the maximum value postdose.</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect for Intact Parathyroid Hormone (iPTH)</title>
          <description>Defined as the maximum value postdose.</description>
          <population>All treated participants</population>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" spread="12.6"/>
                    <measurement group_id="O2" value="38.7" spread="11.9"/>
                    <measurement group_id="O3" value="54.5" spread="13.1"/>
                    <measurement group_id="O4" value="49.9" spread="20.5"/>
                    <measurement group_id="O5" value="62.8" spread="10.9"/>
                    <measurement group_id="O6" value="66.0" spread="20.0"/>
                    <measurement group_id="O7" value="76.3" spread="15.7"/>
                    <measurement group_id="O8" value="64.8" spread="27.8"/>
                    <measurement group_id="O9" value="52.7" spread="20.1"/>
                    <measurement group_id="O10" value="59.7" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Effect of iPTH</title>
        <description>Defined as the time to maximum value postdose.</description>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Effect of iPTH</title>
          <description>Defined as the time to maximum value postdose.</description>
          <population>All treated participants</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="1.0" upper_limit="71.0"/>
                    <measurement group_id="O2" value="11.0" lower_limit="1.0" upper_limit="15.0"/>
                    <measurement group_id="O3" value="25.5" lower_limit="15.0" upper_limit="29.0"/>
                    <measurement group_id="O4" value="22.0" lower_limit="3.0" upper_limit="43.0"/>
                    <measurement group_id="O5" value="22.0" lower_limit="1.0" upper_limit="29.0"/>
                    <measurement group_id="O6" value="22.0" lower_limit="8.0" upper_limit="50.0"/>
                    <measurement group_id="O7" value="15.0" lower_limit="1.0" upper_limit="50.0"/>
                    <measurement group_id="O8" value="25.5" lower_limit="1.0" upper_limit="71.0"/>
                    <measurement group_id="O9" value="11.0" lower_limit="1.0" upper_limit="57.0"/>
                    <measurement group_id="O10" value="18.5" lower_limit="8.0" upper_limit="43.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for iPTH</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Day 0 to Day 29 (AUC0-29) for iPTH</title>
          <population>All treated participants</population>
          <units>days*ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="817" spread="295"/>
                    <measurement group_id="O2" value="823" spread="202"/>
                    <measurement group_id="O3" value="1234" spread="341"/>
                    <measurement group_id="O4" value="1002" spread="405"/>
                    <measurement group_id="O5" value="1270" spread="198"/>
                    <measurement group_id="O6" value="1240" spread="342"/>
                    <measurement group_id="O7" value="1422" spread="411"/>
                    <measurement group_id="O8" value="1235" spread="488"/>
                    <measurement group_id="O9" value="1074" spread="406"/>
                    <measurement group_id="O10" value="1239" spread="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From Day 0 to the Last Sampling Timepoint (AUC0-t) for iPTH</title>
        <time_frame>Predose up to day 29 for participants receiving 0.1 or 0.3 mg/kg romosozumab, up to day 57 for participants receiving 1 or 3 mg/kg romosozumab, and up to day 85 for participants receiving 5 or 10 mg/kg romosozumab.</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Day 0 to the Last Sampling Timepoint (AUC0-t) for iPTH</title>
          <population>All treated participants</population>
          <units>days*ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1592" spread="689"/>
                    <measurement group_id="O2" value="823" spread="202"/>
                    <measurement group_id="O3" value="1234" spread="341"/>
                    <measurement group_id="O4" value="1971" spread="850"/>
                    <measurement group_id="O5" value="2523" spread="406"/>
                    <measurement group_id="O6" value="3483" spread="1057"/>
                    <measurement group_id="O7" value="4195" spread="1144"/>
                    <measurement group_id="O8" value="3100" spread="1077"/>
                    <measurement group_id="O9" value="2072" spread="749"/>
                    <measurement group_id="O10" value="3515" spread="1127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Sclerostin</title>
        <time_frame>Baseline and days 15, 29, 43, 57, 71, and 85</time_frame>
        <population>All treated participants; only participants who received ≥ 1 mg/kg romosozumab/placebo were assessed after day 29 and only participants who received 5 or 10 mg/kg romosozumab/placebo were assessed on days 71 and 85.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Sclerostin</title>
          <population>All treated participants; only participants who received ≥ 1 mg/kg romosozumab/placebo were assessed after day 29 and only participants who received 5 or 10 mg/kg romosozumab/placebo were assessed on days 71 and 85.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="54.3"/>
                    <measurement group_id="O2" value="465.5" spread="49.9"/>
                    <measurement group_id="O3" value="835.1" spread="130.4"/>
                    <measurement group_id="O4" value="2123.8" spread="377.6"/>
                    <measurement group_id="O5" value="7965.9" spread="792.9"/>
                    <measurement group_id="O6" value="12375.7" spread="1375.4"/>
                    <measurement group_id="O7" value="17774.8" spread="2444.0"/>
                    <measurement group_id="O8" value="6.7" spread="11.4"/>
                    <measurement group_id="O9" value="3776.0" spread="461.5"/>
                    <measurement group_id="O10" value="14230.0" spread="2428.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="7.0"/>
                    <measurement group_id="O2" value="129.0" spread="33.3"/>
                    <measurement group_id="O3" value="183.0" spread="19.6"/>
                    <measurement group_id="O4" value="717.4" spread="92.4"/>
                    <measurement group_id="O5" value="5140.2" spread="373.7"/>
                    <measurement group_id="O6" value="9763.2" spread="1252.8"/>
                    <measurement group_id="O7" value="18870.9" spread="2707.3"/>
                    <measurement group_id="O8" value="-4.3" spread="8.7"/>
                    <measurement group_id="O9" value="816.7" spread="222.3"/>
                    <measurement group_id="O10" value="11715.5" spread="2177.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="14.1"/>
                    <measurement group_id="O4" value="223.2" spread="18.1"/>
                    <measurement group_id="O5" value="1988.3" spread="339.9"/>
                    <measurement group_id="O6" value="4968.7" spread="714.7"/>
                    <measurement group_id="O7" value="13902.7" spread="2381.9"/>
                    <measurement group_id="O8" value="4.9" spread="8.7"/>
                    <measurement group_id="O9" value="196.1" spread="48.7"/>
                    <measurement group_id="O10" value="4576.0" spread="1086.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="8.6"/>
                    <measurement group_id="O4" value="83.4" spread="14.5"/>
                    <measurement group_id="O5" value="810.2" spread="169.9"/>
                    <measurement group_id="O6" value="2004.9" spread="421.5"/>
                    <measurement group_id="O7" value="6469.6" spread="1000.3"/>
                    <measurement group_id="O8" value="15.6" spread="0.6"/>
                    <measurement group_id="O9" value="49.9" spread="17.4"/>
                    <measurement group_id="O10" value="1430.0" spread="538.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.9" spread="88.3"/>
                    <measurement group_id="O6" value="610.4" spread="151.6"/>
                    <measurement group_id="O7" value="2080.8" spread="689.0"/>
                    <measurement group_id="O8" value="-5.5" spread="5.4"/>
                    <measurement group_id="O10" value="426.9" spread="119.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="16.6"/>
                    <measurement group_id="O6" value="232.1" spread="49.0"/>
                    <measurement group_id="O7" value="758.0" spread="270.1"/>
                    <measurement group_id="O8" value="0.8" spread="13.4"/>
                    <measurement group_id="O10" value="109.8" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Calcium Over Time</title>
        <time_frame>Dday 1 predose and at 4, 6, 8, 10, and 12 hours, days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85</time_frame>
        <population>All treated participants; only participants who received ≥ 1 mg/kg romosozumab/placebo were assessed after day 29 and only participants who received 5 or 10 mg/kg romosozumab/placebo were assessed after day 57.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Calcium Over Time</title>
          <population>All treated participants; only participants who received ≥ 1 mg/kg romosozumab/placebo were assessed after day 29 and only participants who received 5 or 10 mg/kg romosozumab/placebo were assessed after day 57.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.49" spread="0.34"/>
                    <measurement group_id="O2" value="9.45" spread="0.38"/>
                    <measurement group_id="O3" value="9.50" spread="0.33"/>
                    <measurement group_id="O4" value="9.48" spread="0.27"/>
                    <measurement group_id="O5" value="9.42" spread="0.25"/>
                    <measurement group_id="O6" value="9.53" spread="0.26"/>
                    <measurement group_id="O7" value="9.38" spread="0.24"/>
                    <measurement group_id="O8" value="9.60" spread="0.22"/>
                    <measurement group_id="O9" value="9.23" spread="0.15"/>
                    <measurement group_id="O10" value="9.37" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Hour 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.46" spread="0.30"/>
                    <measurement group_id="O2" value="9.62" spread="0.19"/>
                    <measurement group_id="O3" value="9.45" spread="0.26"/>
                    <measurement group_id="O4" value="9.38" spread="0.16"/>
                    <measurement group_id="O5" value="9.38" spread="0.15"/>
                    <measurement group_id="O6" value="9.59" spread="0.27"/>
                    <measurement group_id="O7" value="9.35" spread="0.40"/>
                    <measurement group_id="O8" value="9.45" spread="0.21"/>
                    <measurement group_id="O9" value="9.43" spread="0.22"/>
                    <measurement group_id="O10" value="9.40" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Hour 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.49" spread="0.26"/>
                    <measurement group_id="O2" value="9.38" spread="0.22"/>
                    <measurement group_id="O3" value="9.50" spread="0.14"/>
                    <measurement group_id="O4" value="9.47" spread="0.17"/>
                    <measurement group_id="O5" value="9.60" spread="0.24"/>
                    <measurement group_id="O6" value="9.48" spread="0.35"/>
                    <measurement group_id="O7" value="9.25" spread="0.36"/>
                    <measurement group_id="O8" value="9.18" spread="0.13"/>
                    <measurement group_id="O9" value="9.38" spread="0.31"/>
                    <measurement group_id="O10" value="9.40" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Hour 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.38" spread="0.22"/>
                    <measurement group_id="O2" value="9.47" spread="0.29"/>
                    <measurement group_id="O3" value="9.33" spread="0.23"/>
                    <measurement group_id="O4" value="9.29" spread="0.18"/>
                    <measurement group_id="O5" value="9.28" spread="0.12"/>
                    <measurement group_id="O6" value="9.42" spread="0.28"/>
                    <measurement group_id="O7" value="9.27" spread="0.33"/>
                    <measurement group_id="O8" value="9.38" spread="0.21"/>
                    <measurement group_id="O9" value="9.35" spread="0.10"/>
                    <measurement group_id="O10" value="9.22" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Hour 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.53" spread="0.26"/>
                    <measurement group_id="O2" value="9.62" spread="0.31"/>
                    <measurement group_id="O3" value="9.50" spread="0.27"/>
                    <measurement group_id="O4" value="9.40" spread="0.30"/>
                    <measurement group_id="O5" value="9.38" spread="0.19"/>
                    <measurement group_id="O6" value="9.36" spread="0.31"/>
                    <measurement group_id="O7" value="9.28" spread="0.27"/>
                    <measurement group_id="O8" value="9.50" spread="0.22"/>
                    <measurement group_id="O9" value="9.45" spread="0.16"/>
                    <measurement group_id="O10" value="9.42" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Hour 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.53" spread="0.28"/>
                    <measurement group_id="O2" value="9.55" spread="0.27"/>
                    <measurement group_id="O3" value="9.57" spread="0.31"/>
                    <measurement group_id="O4" value="9.49" spread="0.31"/>
                    <measurement group_id="O5" value="9.37" spread="0.34"/>
                    <measurement group_id="O6" value="9.52" spread="0.26"/>
                    <measurement group_id="O7" value="9.27" spread="0.34"/>
                    <measurement group_id="O8" value="9.40" spread="0.24"/>
                    <measurement group_id="O9" value="9.47" spread="0.19"/>
                    <measurement group_id="O10" value="9.45" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.46" spread="0.34"/>
                    <measurement group_id="O2" value="9.55" spread="0.21"/>
                    <measurement group_id="O3" value="9.23" spread="0.28"/>
                    <measurement group_id="O4" value="9.39" spread="0.21"/>
                    <measurement group_id="O5" value="9.37" spread="0.33"/>
                    <measurement group_id="O6" value="9.46" spread="0.29"/>
                    <measurement group_id="O7" value="9.23" spread="0.29"/>
                    <measurement group_id="O8" value="8.55" spread="1.77"/>
                    <measurement group_id="O9" value="9.05" spread="0.41"/>
                    <measurement group_id="O10" value="9.28" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.30" spread="0.61"/>
                    <measurement group_id="O2" value="9.37" spread="0.29"/>
                    <measurement group_id="O3" value="9.25" spread="0.39"/>
                    <measurement group_id="O4" value="9.20" spread="0.34"/>
                    <measurement group_id="O5" value="9.35" spread="0.14"/>
                    <measurement group_id="O6" value="9.38" spread="0.41"/>
                    <measurement group_id="O7" value="9.18" spread="0.17"/>
                    <measurement group_id="O8" value="9.40" spread="0.24"/>
                    <measurement group_id="O9" value="9.13" spread="0.51"/>
                    <measurement group_id="O10" value="9.27" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.49" spread="0.25"/>
                    <measurement group_id="O2" value="9.38" spread="0.27"/>
                    <measurement group_id="O3" value="9.37" spread="0.27"/>
                    <measurement group_id="O4" value="9.18" spread="0.64"/>
                    <measurement group_id="O5" value="9.27" spread="0.12"/>
                    <measurement group_id="O6" value="9.40" spread="0.30"/>
                    <measurement group_id="O7" value="9.13" spread="0.22"/>
                    <measurement group_id="O8" value="9.23" spread="0.50"/>
                    <measurement group_id="O9" value="8.88" spread="0.84"/>
                    <measurement group_id="O10" value="9.18" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" spread="0.36"/>
                    <measurement group_id="O2" value="9.38" spread="0.21"/>
                    <measurement group_id="O3" value="9.37" spread="0.25"/>
                    <measurement group_id="O4" value="9.38" spread="0.24"/>
                    <measurement group_id="O5" value="9.32" spread="0.25"/>
                    <measurement group_id="O6" value="9.24" spread="0.26"/>
                    <measurement group_id="O7" value="9.15" spread="0.18"/>
                    <measurement group_id="O8" value="9.55" spread="0.17"/>
                    <measurement group_id="O9" value="9.20" spread="0.15"/>
                    <measurement group_id="O10" value="9.12" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.56" spread="0.26"/>
                    <measurement group_id="O2" value="9.45" spread="0.29"/>
                    <measurement group_id="O3" value="9.45" spread="0.26"/>
                    <measurement group_id="O4" value="9.51" spread="0.20"/>
                    <measurement group_id="O5" value="9.35" spread="0.10"/>
                    <measurement group_id="O6" value="9.36" spread="0.26"/>
                    <measurement group_id="O7" value="9.18" spread="0.15"/>
                    <measurement group_id="O8" value="9.35" spread="0.24"/>
                    <measurement group_id="O9" value="9.32" spread="0.19"/>
                    <measurement group_id="O10" value="9.23" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.41" spread="0.31"/>
                    <measurement group_id="O2" value="9.45" spread="0.20"/>
                    <measurement group_id="O3" value="9.28" spread="0.23"/>
                    <measurement group_id="O4" value="9.36" spread="0.44"/>
                    <measurement group_id="O5" value="9.23" spread="0.10"/>
                    <measurement group_id="O6" value="9.33" spread="0.40"/>
                    <measurement group_id="O7" value="8.93" spread="0.28"/>
                    <measurement group_id="O8" value="9.30" spread="0.22"/>
                    <measurement group_id="O9" value="9.18" spread="0.29"/>
                    <measurement group_id="O10" value="9.20" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.32" spread="0.29"/>
                    <measurement group_id="O2" value="9.38" spread="0.33"/>
                    <measurement group_id="O3" value="9.07" spread="0.24"/>
                    <measurement group_id="O4" value="9.39" spread="0.25"/>
                    <measurement group_id="O5" value="9.30" spread="0.39"/>
                    <measurement group_id="O6" value="9.19" spread="0.36"/>
                    <measurement group_id="O7" value="8.70" spread="0.75"/>
                    <measurement group_id="O8" value="9.30" spread="0.22"/>
                    <measurement group_id="O9" value="9.13" spread="0.29"/>
                    <measurement group_id="O10" value="9.18" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.39" spread="0.26"/>
                    <measurement group_id="O2" value="9.60" spread="0.17"/>
                    <measurement group_id="O3" value="9.40" spread="0.32"/>
                    <measurement group_id="O4" value="9.26" spread="0.21"/>
                    <measurement group_id="O5" value="9.22" spread="0.19"/>
                    <measurement group_id="O6" value="9.06" spread="0.35"/>
                    <measurement group_id="O7" value="8.97" spread="0.18"/>
                    <measurement group_id="O8" value="9.33" spread="0.22"/>
                    <measurement group_id="O9" value="9.28" spread="0.33"/>
                    <measurement group_id="O10" value="9.00" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.35" spread="0.33"/>
                    <measurement group_id="O2" value="9.53" spread="0.45"/>
                    <measurement group_id="O3" value="9.18" spread="0.35"/>
                    <measurement group_id="O4" value="9.33" spread="0.32"/>
                    <measurement group_id="O5" value="9.22" spread="0.17"/>
                    <measurement group_id="O6" value="9.14" spread="0.47"/>
                    <measurement group_id="O7" value="8.90" spread="0.23"/>
                    <measurement group_id="O8" value="9.48" spread="0.13"/>
                    <measurement group_id="O9" value="9.18" spread="0.22"/>
                    <measurement group_id="O10" value="9.08" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.49" spread="0.32"/>
                    <measurement group_id="O2" value="9.58" spread="0.22"/>
                    <measurement group_id="O3" value="9.40" spread="0.26"/>
                    <measurement group_id="O4" value="9.44" spread="0.37"/>
                    <measurement group_id="O5" value="9.20" spread="0.27"/>
                    <measurement group_id="O6" value="9.32" spread="0.28"/>
                    <measurement group_id="O7" value="8.95" spread="0.19"/>
                    <measurement group_id="O8" value="9.38" spread="0.13"/>
                    <measurement group_id="O9" value="9.17" spread="0.21"/>
                    <measurement group_id="O10" value="9.15" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40" spread="0.45"/>
                    <measurement group_id="O4" value="9.33" spread="0.26"/>
                    <measurement group_id="O5" value="9.23" spread="0.30"/>
                    <measurement group_id="O6" value="9.00" spread="0.26"/>
                    <measurement group_id="O7" value="9.07" spread="0.26"/>
                    <measurement group_id="O8" value="9.25" spread="0.30"/>
                    <measurement group_id="O9" value="9.18" spread="0.35"/>
                    <measurement group_id="O10" value="9.00" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.33" spread="0.39"/>
                    <measurement group_id="O4" value="9.32" spread="0.21"/>
                    <measurement group_id="O5" value="9.37" spread="0.31"/>
                    <measurement group_id="O6" value="9.23" spread="0.36"/>
                    <measurement group_id="O7" value="8.90" spread="0.26"/>
                    <measurement group_id="O8" value="9.28" spread="0.33"/>
                    <measurement group_id="O9" value="9.25" spread="0.25"/>
                    <measurement group_id="O10" value="9.15" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.35" spread="0.26"/>
                    <measurement group_id="O4" value="9.30" spread="0.41"/>
                    <measurement group_id="O5" value="9.03" spread="0.21"/>
                    <measurement group_id="O6" value="9.40" spread="0.34"/>
                    <measurement group_id="O7" value="8.98" spread="0.19"/>
                    <measurement group_id="O8" value="9.33" spread="0.33"/>
                    <measurement group_id="O9" value="9.43" spread="0.50"/>
                    <measurement group_id="O10" value="9.07" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.46" spread="0.30"/>
                    <measurement group_id="O4" value="9.47" spread="0.36"/>
                    <measurement group_id="O5" value="9.35" spread="0.29"/>
                    <measurement group_id="O6" value="9.18" spread="0.49"/>
                    <measurement group_id="O7" value="9.28" spread="0.17"/>
                    <measurement group_id="O8" value="9.33" spread="0.29"/>
                    <measurement group_id="O9" value="9.25" spread="0.27"/>
                    <measurement group_id="O10" value="9.02" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.22" spread="0.15"/>
                    <measurement group_id="O6" value="9.28" spread="0.42"/>
                    <measurement group_id="O7" value="8.90" spread="0.36"/>
                    <measurement group_id="O8" value="9.25" spread="0.07"/>
                    <measurement group_id="O10" value="9.18" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.36" spread="0.18"/>
                    <measurement group_id="O6" value="9.47" spread="0.47"/>
                    <measurement group_id="O7" value="9.05" spread="0.36"/>
                    <measurement group_id="O8" value="9.20" spread="0.14"/>
                    <measurement group_id="O10" value="9.20" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.30" spread="0.24"/>
                    <measurement group_id="O6" value="9.31" spread="0.32"/>
                    <measurement group_id="O7" value="9.07" spread="0.40"/>
                    <measurement group_id="O8" value="9.20" spread="0.00"/>
                    <measurement group_id="O10" value="9.12" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.12" spread="0.08"/>
                    <measurement group_id="O6" value="9.47" spread="0.35"/>
                    <measurement group_id="O7" value="8.82" spread="0.31"/>
                    <measurement group_id="O8" value="9.10" spread="0.28"/>
                    <measurement group_id="O10" value="9.05" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ionized Calcium Over Time</title>
        <time_frame>Day 1 predose and at 4, 6, 8, 10, 12 hours, days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85</time_frame>
        <population>All treated participants; only participants who received ≥ 1 mg/kg romosozumab/placebo were assessed after day 29 and only participants who received 5 or 10 mg/kg romosozumab/placebo were assessed after day 57.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo SC</title>
            <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
          </group>
          <group group_id="O2">
            <title>Romosozumab 0.1 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
          </group>
          <group group_id="O3">
            <title>Romosozumab 0.3 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
          </group>
          <group group_id="O4">
            <title>Romosozumab 1.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O5">
            <title>Romosozumab 3.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O6">
            <title>Romosozumab 5.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O7">
            <title>Romosozumab 10.0 mg/kg SC</title>
            <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O8">
            <title>Placebo IV</title>
            <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
          </group>
          <group group_id="O9">
            <title>Romosozumab 1.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
          </group>
          <group group_id="O10">
            <title>Romosozumab 5.0 mg/kg IV</title>
            <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab</description>
          </group>
        </group_list>
        <measure>
          <title>Ionized Calcium Over Time</title>
          <population>All treated participants; only participants who received ≥ 1 mg/kg romosozumab/placebo were assessed after day 29 and only participants who received 5 or 10 mg/kg romosozumab/placebo were assessed after day 57.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" spread="0.20"/>
                    <measurement group_id="O2" value="4.95" spread="0.18"/>
                    <measurement group_id="O3" value="5.02" spread="0.16"/>
                    <measurement group_id="O4" value="5.01" spread="0.18"/>
                    <measurement group_id="O5" value="4.88" spread="0.08"/>
                    <measurement group_id="O6" value="5.07" spread="0.18"/>
                    <measurement group_id="O7" value="4.85" spread="0.10"/>
                    <measurement group_id="O8" value="5.30" spread="0.12"/>
                    <measurement group_id="O9" value="5.18" spread="0.15"/>
                    <measurement group_id="O10" value="5.27" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Hour 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="0.20"/>
                    <measurement group_id="O2" value="5.02" spread="0.17"/>
                    <measurement group_id="O3" value="5.10" spread="0.13"/>
                    <measurement group_id="O4" value="5.11" spread="0.24"/>
                    <measurement group_id="O5" value="5.03" spread="0.10"/>
                    <measurement group_id="O6" value="5.12" spread="0.32"/>
                    <measurement group_id="O7" value="4.95" spread="0.08"/>
                    <measurement group_id="O8" value="5.40" spread="0.14"/>
                    <measurement group_id="O9" value="5.35" spread="0.18"/>
                    <measurement group_id="O10" value="5.40" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Hour 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.97" spread="0.19"/>
                    <measurement group_id="O2" value="4.93" spread="0.10"/>
                    <measurement group_id="O3" value="4.98" spread="0.10"/>
                    <measurement group_id="O4" value="4.97" spread="0.21"/>
                    <measurement group_id="O5" value="4.93" spread="0.08"/>
                    <measurement group_id="O6" value="5.06" spread="0.24"/>
                    <measurement group_id="O7" value="4.87" spread="0.12"/>
                    <measurement group_id="O8" value="5.10" spread="0.14"/>
                    <measurement group_id="O9" value="5.28" spread="0.15"/>
                    <measurement group_id="O10" value="5.30" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Hour 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="0.14"/>
                    <measurement group_id="O2" value="4.92" spread="0.15"/>
                    <measurement group_id="O3" value="5.00" spread="0.11"/>
                    <measurement group_id="O4" value="5.00" spread="0.21"/>
                    <measurement group_id="O5" value="4.90" spread="0.06"/>
                    <measurement group_id="O6" value="5.04" spread="0.27"/>
                    <measurement group_id="O7" value="4.78" spread="0.12"/>
                    <measurement group_id="O8" value="5.30" spread="0.08"/>
                    <measurement group_id="O9" value="5.28" spread="0.17"/>
                    <measurement group_id="O10" value="5.30" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Hour 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="0.20"/>
                    <measurement group_id="O2" value="5.00" spread="0.09"/>
                    <measurement group_id="O3" value="5.05" spread="0.10"/>
                    <measurement group_id="O4" value="5.11" spread="0.19"/>
                    <measurement group_id="O5" value="4.95" spread="0.15"/>
                    <measurement group_id="O6" value="5.07" spread="0.34"/>
                    <measurement group_id="O7" value="4.88" spread="0.12"/>
                    <measurement group_id="O8" value="5.30" spread="0.12"/>
                    <measurement group_id="O9" value="5.32" spread="0.18"/>
                    <measurement group_id="O10" value="5.38" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Hour 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" spread="0.18"/>
                    <measurement group_id="O2" value="4.95" spread="0.08"/>
                    <measurement group_id="O3" value="5.00" spread="0.15"/>
                    <measurement group_id="O4" value="5.01" spread="0.20"/>
                    <measurement group_id="O5" value="4.93" spread="0.16"/>
                    <measurement group_id="O6" value="5.03" spread="0.30"/>
                    <measurement group_id="O7" value="4.80" spread="0.11"/>
                    <measurement group_id="O8" value="5.28" spread="0.22"/>
                    <measurement group_id="O9" value="5.25" spread="0.10"/>
                    <measurement group_id="O10" value="5.33" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" spread="0.20"/>
                    <measurement group_id="O2" value="5.03" spread="0.16"/>
                    <measurement group_id="O3" value="4.92" spread="0.17"/>
                    <measurement group_id="O4" value="5.03" spread="0.17"/>
                    <measurement group_id="O5" value="4.98" spread="0.12"/>
                    <measurement group_id="O6" value="5.04" spread="0.19"/>
                    <measurement group_id="O7" value="4.88" spread="0.15"/>
                    <measurement group_id="O8" value="5.28" spread="0.10"/>
                    <measurement group_id="O9" value="5.08" spread="0.08"/>
                    <measurement group_id="O10" value="5.18" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.06" spread="0.19"/>
                    <measurement group_id="O2" value="5.00" spread="0.13"/>
                    <measurement group_id="O3" value="4.97" spread="0.14"/>
                    <measurement group_id="O4" value="5.00" spread="0.14"/>
                    <measurement group_id="O5" value="4.95" spread="0.08"/>
                    <measurement group_id="O6" value="5.12" spread="0.20"/>
                    <measurement group_id="O7" value="4.85" spread="0.05"/>
                    <measurement group_id="O8" value="5.28" spread="0.13"/>
                    <measurement group_id="O9" value="5.17" spread="0.12"/>
                    <measurement group_id="O10" value="5.25" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" spread="0.17"/>
                    <measurement group_id="O2" value="4.97" spread="0.15"/>
                    <measurement group_id="O3" value="4.85" spread="0.16"/>
                    <measurement group_id="O4" value="5.03" spread="0.10"/>
                    <measurement group_id="O5" value="4.87" spread="0.12"/>
                    <measurement group_id="O6" value="5.11" spread="0.20"/>
                    <measurement group_id="O7" value="4.82" spread="0.08"/>
                    <measurement group_id="O8" value="5.23" spread="0.17"/>
                    <measurement group_id="O9" value="5.20" spread="0.09"/>
                    <measurement group_id="O10" value="5.17" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" spread="0.18"/>
                    <measurement group_id="O2" value="4.93" spread="0.10"/>
                    <measurement group_id="O3" value="4.88" spread="0.25"/>
                    <measurement group_id="O4" value="5.04" spread="0.12"/>
                    <measurement group_id="O5" value="4.93" spread="0.12"/>
                    <measurement group_id="O6" value="5.04" spread="0.19"/>
                    <measurement group_id="O7" value="4.80" spread="0.06"/>
                    <measurement group_id="O8" value="5.40" spread="0.14"/>
                    <measurement group_id="O9" value="5.18" spread="0.12"/>
                    <measurement group_id="O10" value="5.15" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" spread="0.16"/>
                    <measurement group_id="O2" value="4.91" spread="0.14"/>
                    <measurement group_id="O3" value="4.97" spread="0.12"/>
                    <measurement group_id="O4" value="5.06" spread="0.11"/>
                    <measurement group_id="O5" value="4.88" spread="0.10"/>
                    <measurement group_id="O6" value="5.02" spread="0.14"/>
                    <measurement group_id="O7" value="4.80" spread="0.06"/>
                    <measurement group_id="O8" value="5.23" spread="0.10"/>
                    <measurement group_id="O9" value="5.23" spread="0.12"/>
                    <measurement group_id="O10" value="5.05" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" spread="0.17"/>
                    <measurement group_id="O2" value="4.98" spread="0.08"/>
                    <measurement group_id="O3" value="4.92" spread="0.10"/>
                    <measurement group_id="O4" value="5.01" spread="0.24"/>
                    <measurement group_id="O5" value="4.83" spread="0.10"/>
                    <measurement group_id="O6" value="4.89" spread="0.18"/>
                    <measurement group_id="O7" value="5.00" spread="0.14"/>
                    <measurement group_id="O8" value="5.23" spread="0.17"/>
                    <measurement group_id="O9" value="5.17" spread="0.12"/>
                    <measurement group_id="O10" value="5.07" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" spread="0.14"/>
                    <measurement group_id="O2" value="5.05" spread="0.14"/>
                    <measurement group_id="O3" value="4.93" spread="0.14"/>
                    <measurement group_id="O4" value="5.06" spread="0.17"/>
                    <measurement group_id="O5" value="4.90" spread="0.13"/>
                    <measurement group_id="O6" value="4.92" spread="0.15"/>
                    <measurement group_id="O7" value="5.00" spread="0.11"/>
                    <measurement group_id="O8" value="5.23" spread="0.13"/>
                    <measurement group_id="O9" value="5.20" spread="0.13"/>
                    <measurement group_id="O10" value="5.10" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" spread="0.16"/>
                    <measurement group_id="O2" value="5.10" spread="0.19"/>
                    <measurement group_id="O3" value="4.92" spread="0.12"/>
                    <measurement group_id="O4" value="5.02" spread="0.16"/>
                    <measurement group_id="O5" value="4.83" spread="0.12"/>
                    <measurement group_id="O6" value="4.98" spread="0.19"/>
                    <measurement group_id="O7" value="5.00" spread="0.06"/>
                    <measurement group_id="O8" value="5.20" spread="0.22"/>
                    <measurement group_id="O9" value="5.25" spread="0.12"/>
                    <measurement group_id="O10" value="5.07" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.03" spread="0.17"/>
                    <measurement group_id="O2" value="5.05" spread="0.18"/>
                    <measurement group_id="O3" value="4.82" spread="0.12"/>
                    <measurement group_id="O4" value="4.92" spread="0.16"/>
                    <measurement group_id="O5" value="4.85" spread="0.08"/>
                    <measurement group_id="O6" value="5.08" spread="0.17"/>
                    <measurement group_id="O7" value="5.05" spread="0.08"/>
                    <measurement group_id="O8" value="5.18" spread="0.24"/>
                    <measurement group_id="O9" value="5.12" spread="0.15"/>
                    <measurement group_id="O10" value="5.05" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13" spread="0.17"/>
                    <measurement group_id="O2" value="5.05" spread="0.08"/>
                    <measurement group_id="O3" value="4.92" spread="0.17"/>
                    <measurement group_id="O4" value="5.02" spread="0.20"/>
                    <measurement group_id="O5" value="4.85" spread="0.08"/>
                    <measurement group_id="O6" value="5.22" spread="0.12"/>
                    <measurement group_id="O7" value="5.03" spread="0.16"/>
                    <measurement group_id="O8" value="5.28" spread="0.17"/>
                    <measurement group_id="O9" value="5.22" spread="0.10"/>
                    <measurement group_id="O10" value="5.13" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.16" spread="0.17"/>
                    <measurement group_id="O4" value="4.96" spread="0.14"/>
                    <measurement group_id="O5" value="5.07" spread="0.16"/>
                    <measurement group_id="O6" value="5.11" spread="0.18"/>
                    <measurement group_id="O7" value="4.96" spread="0.16"/>
                    <measurement group_id="O8" value="5.28" spread="0.13"/>
                    <measurement group_id="O9" value="5.18" spread="0.10"/>
                    <measurement group_id="O10" value="5.18" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" spread="0.23"/>
                    <measurement group_id="O4" value="4.99" spread="0.15"/>
                    <measurement group_id="O5" value="5.22" spread="0.13"/>
                    <measurement group_id="O6" value="5.26" spread="0.21"/>
                    <measurement group_id="O7" value="5.02" spread="0.08"/>
                    <measurement group_id="O8" value="5.23" spread="0.17"/>
                    <measurement group_id="O9" value="5.30" spread="0.13"/>
                    <measurement group_id="O10" value="5.18" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" spread="0.19"/>
                    <measurement group_id="O4" value="5.19" spread="0.16"/>
                    <measurement group_id="O5" value="5.20" spread="0.11"/>
                    <measurement group_id="O6" value="5.16" spread="0.11"/>
                    <measurement group_id="O7" value="5.00" spread="0.13"/>
                    <measurement group_id="O8" value="5.28" spread="0.15"/>
                    <measurement group_id="O9" value="5.32" spread="0.13"/>
                    <measurement group_id="O10" value="5.15" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="4"/>
                    <count group_id="O9" value="6"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" spread="0.14"/>
                    <measurement group_id="O4" value="5.22" spread="0.14"/>
                    <measurement group_id="O5" value="5.22" spread="0.10"/>
                    <measurement group_id="O6" value="5.21" spread="0.15"/>
                    <measurement group_id="O7" value="5.18" spread="0.13"/>
                    <measurement group_id="O8" value="5.33" spread="0.17"/>
                    <measurement group_id="O9" value="5.23" spread="0.08"/>
                    <measurement group_id="O10" value="5.25" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" spread="0.11"/>
                    <measurement group_id="O6" value="5.22" spread="0.18"/>
                    <measurement group_id="O7" value="5.13" spread="0.14"/>
                    <measurement group_id="O8" value="5.15" spread="0.07"/>
                    <measurement group_id="O10" value="5.17" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.18" spread="0.08"/>
                    <measurement group_id="O6" value="5.38" spread="0.16"/>
                    <measurement group_id="O7" value="5.12" spread="0.18"/>
                    <measurement group_id="O8" value="5.30" spread="0.28"/>
                    <measurement group_id="O10" value="5.20" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="0.08"/>
                    <measurement group_id="O6" value="5.30" spread="0.17"/>
                    <measurement group_id="O7" value="5.15" spread="0.19"/>
                    <measurement group_id="O8" value="5.15" spread="0.07"/>
                    <measurement group_id="O10" value="5.27" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" spread="0.11"/>
                    <measurement group_id="O6" value="5.36" spread="0.13"/>
                    <measurement group_id="O7" value="5.13" spread="0.22"/>
                    <measurement group_id="O8" value="5.20" spread="0.14"/>
                    <measurement group_id="O10" value="5.23" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the first dose of treatment up until day 29 for the 0.1 mg/kg and 0.3 mg/kg SC treatment groups, up to 57 days for the 1 mg/kg and 3 mg/kg IV/SC groups and for up to 85 days for the 5 mg/kg and 10 mg/kg SC/IV groups.</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo SC</title>
          <description>Participants received a single subcutaneous (SC) injection of matching placebo.</description>
        </group>
        <group group_id="E2">
          <title>Placebo IV</title>
          <description>Participants received a single intravenous (IV) injection of matching placebo.</description>
        </group>
        <group group_id="E3">
          <title>Romosozumab 0.1 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 0.1 mg/kg romosozumab.</description>
        </group>
        <group group_id="E4">
          <title>Romosozumab 0.3 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 0.3 mg/kg romosozumab.</description>
        </group>
        <group group_id="E5">
          <title>Romosozumab 1.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 1.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="E6">
          <title>Romosozumab 10.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 10.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="E7">
          <title>Romosozumab 3.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 3.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="E8">
          <title>Romosozumab 5.0 mg/kg SC</title>
          <description>Participants received a single subcutaneous injection of 5.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="E9">
          <title>Romosozumab 1.0 mg/kg IV</title>
          <description>Participants received a single intravenous injection of 1.0 mg/kg romosozumab.</description>
        </group>
        <group group_id="E10">
          <title>Romosozumab 5.0 mg/kg IV</title>
          <description>Participants received a single intravenous injection of 5.0 mg/kg romosozumab.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>BASEDOW'S DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLEPHARITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>APHTHOUS STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>LIP DRY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ORAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>AXILLARY PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>THIRST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HORDEOLUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>TINEA PEDIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BREAST TENDERNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

